AXSM News and Press, Axsome Therapeutics Inc. From 05/11/24

2024-05-11 09:00:00 ET Stocks that can triple in six years aren't easy to find. Doing so requires a compound annual growth rate of 20.1%, well above the broader market's historical performance. However, it isn't impossible. Let's consider two stocks that may have what it takes to pull i...

2024-05-10 04:36:58 ET Summary Axsome Therapeutics develops treatments for CNS conditions, with two commercial products: Auvelity for major depressive disorders and Sunosi for sleep disorders. The company has a diverse pipeline targeting illnesses such as Alzheimer's disease, smok...

2024-05-09 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-06 22:30:02 ET Citigroup analyst issues BUY recommendation for AXSM on May 6, 2024 08:59PM ET. The previous analyst recommendation was Buy. AXSM was trading at $75.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...

2024-05-06 13:00:29 ET Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q1 2024 Earnings Call May 06, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Tran...

2024-05-06 11:55:24 ET Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Conference Call May 06, 2024, 08:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Off...

2024-05-06 07:01:57 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Axsome Therapeutics Q1 2024 Earnings Preview Axsome Therapeuti...

PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....

Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-yea...

2024-05-03 12:54:44 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Axsome Therapeutics stock rises on upgrade to Overweight at Morgan Sta...